DARWINHEALTH LEADERSHIP

Professor Andrea Califano, Dr.

Co-founder and
Chief Scientific Advisor

Andrea Califano, Co-Founder and Chief Scientific Advisor, DarwinHealth™ , is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center.

Gideon Bosker, MD

Co-founder and
Chief Executive Officer

Gideon Bosker, MD, the co-founder and CEO of DarwinHealth™, brings to this "precision-focused" organization the knowledge, principles, and aspirations nurtured during his 15-year career as an academic scholar and clinician.

  • More

    He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics.

    After completing a doctoral thesis in physics at the University of Florence, Italy, Dr. Califano worked at the IBM TJ Watson Research Center, where he became involved in computational biology in 1990. In 1997 he became program director of the IBM Computational Biology Center. In 2000 he co-founded First Genetic Trust, Inc. to pursue translational genomics research. Finally, he joined Columbia in 2003.

    Dr. Califano is very active nationally, serving on numerous editorial and scientific advisory boards, including the Board of Scientific Advisors of the National Cancer Institute, St. Jude Children’s Hospital, The MIT Koch Cancer Center, Cancer Genetics Inc., and Thermo Fisher Scientific Inc., among others. He has served as chair or co-chair of many international conferences and meetings, including the annual meeting of the American Association for Cancer Research (AACR); the RECOMB-ISCB Conference on Regulatory and Systems Genomics, with DREAM Challenges; Keystone Conferences; as well as several special conferences of the AACR on genomics and cancer systems biology.

  • Close

    .

  • More

    While a faculty member at the Yale University School of Medicine and Oregon Health Sciences University, Dr. Bosker authored and/or or edited multiple core textbooks and journals in clinical medicine and pharmacotherapeutics among them, Pharmatecture: Minimizing Medications to Maximize Results, The Manual of Emergency Medicine Therapeutics, Clinical Consensus Reports, The Textbook of Primary and Acute Care Medicine, The QuickConsult Manual of Primary Care Medicine, Geriatric Emergency Medicine, and Pills that Work, Pills that Don't.

    Under his direction over the past 10 years, as Founder and CEO of CMEducation Resources, this globally-focused company has produced award-winning, live and digitally-based independent medical education programming in the fields of clinical oncology, biologics-based therapy, genomics-driven precision cancer medicine, diabetes, thrombosis, neurodegenerative disease, obesity, cardiovascular disease, medical diagnostics, genetic screening, and metabolic disorders. These multi-platform initiatives, deploying proprietary technologies and reaching tens of thousands of physicians worldwide, have been implemented under the sponsorship of leading biopharmaceutical and diagnostics companies, including Bayer Healthcare, Pfizer, Bristol Myers Squibb, Genentech, Roche, Daiichi Sankyo, Ipsen, Novo Nordisk, Astra Zeneca, Eisai, Sanofi, Regeneron, Amgen, Genzyme, Natera, Teva, and Quest.

    His leadership roles at both DarwinHealth™ and CMEducation have been instrumental in galvanizing an international network of the world's leading scientists, clinical investigators, strategists, and industry leaders who share a commitment for advancing the frontiers and foundations of cancer medicine — as well as other critical disease states with unmet therapeutic needs — based on scientifically rigorous and innovative discoveries and technologies.

  • Close

    .

Mariano Alvarez, PhD

Chief Scientific Officer

Dr. Alvarez obtained his Ph.D. in Chemistry and Molecular Biology from the University of Buenos Aires, Argentina, where his work and discovery programs focused on the interactions between tumor cells and the host immune system. Following his formal education, Dr. Alvarez was appointed Senior Scientist at a biotech company where he employed gene expression profile analysis to characterize molecular changes in the brain that were triggered by tumor growth at distal sites.

  • More

    After postdoctoral training in the Califano Lab at Columbia University, Dr. Alvarez was appointed Research Scientist in the Department of Systems Biology at Columbia University.

     

    Over the past nine years, in conjunction with Professor Califano, Dr. Alvarez developed the IP and core algorithms, including VIPER, that are currently deployed by DarwinHealth™ and that underpin the company’s foundational, oncotecture-driven technology platform. The platform has been successfully deployed for drug discovery, biomarker elucidation, and proteomic profiling across multiple disease states, with a focus on cancer.

     

    This proprietary technology, the details of which have been published in the world’s leading scientific and medical journals, includes methods for the reverse engineering of regulatory networks, assessment of protein dysregulation, and computation-based inference of cell state checkpoints. His work related to the elucidation of targetable tumor checkpoints in cancer, identification of regulatory nodes implicated in neurodegeneration and behavioral disorders, and characterization of drug mechanism of action and synergy has been reported in more than 25 manuscripts published in top-tier scientific journals

    .

  • Close

    .

Yao Shen, PhD

Director of Systems Pharmacology

Senior Data Scientist

Dr. Shen received her Ph.D. in Computational Chemistry and a M.Sc. in Computer Science from the University of Notre Dame. Her Ph.D. thesis focused on applying structural-based and ligand-based drug discovery techniques to predict hits for essential genes in pathogens identified using metabolic network analysis.

  • More

    Subsequently, she joined the laboratory of Dr. Andrea Califano at Columbia University as a postdoctoral scientist, where she worked on projects involving inferring compound mode-of-action, predicting synergistic compound combinations, and methods for identifying and reversing drug resistance using systems biology-based approaches.

  • Close

    .

Stuart Andrews, PhD

Director of Data Science

Dr. Andrews received his PhD from the department of Computer Science at Brown University, Providence, RI, where he developed machine learning algorithms harnessing large quantities of ambiguous data for classification problems, including problems of in-silico, molecular docking-based, candidate drug screening.

  • More

    He continued research on data-driven inference during his postdoctoral training in the Department of Computer Science at Columbia University, where he developed methods for network inference applicable to social and biological networks.  Following this, Dr. Andrews brought his expertise in big data and high performance computing to the field of bioinformatics, where he developed pipelines for RNA-seq at Weill Cornell Medical College in New York.  He has spent the last several years as Associate Research Scientist in the Laboratory of Personalized Genomic Medicine in the Department of Pathology and Cell Biology at Columbia University Medical Center, where he worked to help develop, validate, and oversee the first comprehensive, genome-wide, whole-exome and transcriptome test for clinical cancer diagnosis.

     

  • Close

    .

Li Wang, PhD

Senior Director of Computational Systems Biology

Dr. Li Wang brings to DarwinHealth™ a multi-disciplinary background in cell biology, computer sciences, statistics, and computational biology, which provides unique biological and technical advantages for drug discovery and biomarker development within the framework of systems biology.

  • More

    After obtaining her Ph.D. in Computational Biology, she worked at Novartis and the Cancer Cell Line Encyclopedia project. Over the past 12 years, Dr. Wang successfully developed a number of innovative mathematical models that have enabled scientists in the life sciences to bridge large-scale genomic data, including those at the interactome, transcriptome and phenome levels. In addition, she brings unique expertise in the use of machine learning techniques, which she has employed to refine integrative approaches in systems biology and to build predictive models for tens of thousands of compounds. Some of her pivotal discoveries have led to the development of novel drug targets and innovative therapeutic strategies. Most recently, Dr. Wang was on the research staff of the Ichan School of medicine at Mount Sinai School of Medicine, where she worked closely with clinicians in conducting integrative and systematic analysis of cancer genomics, for which she won a Young Investigator Award from the Prostate Cancer Foundation.

  • Close

    .

(646) 661-5604

Lasker Biomedical Research Building  |  3960 Broadway, Suite 540  |  New York, NY 10032

info@darwinhealth.com

 

All contents © 2017 DarwinHealth.  All rights reserved.  Privacy policy.